disopyramide has been researched along with Cardiomyopathy, Hypertrophic Obstructive in 52 studies
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Disopyramide as an antiarrhythmic can be prescribed to patients with atrial fibrillation and, owing to its negative inotropic effect, to patients with hypertrophic obstructive cardiomyopathy." | 3.69 | Heart conduction disturbances and cardiovascular collapse after disopyramide and low-dose metoprolol in a patient with hypertrophic obstructive cardiomyopathy. ( Horvat, M; Pernat, A; Pohar, B, 1997) |
| "Disopyramide was more effective than propranolol (p less than 0." | 2.66 | Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration. ( Pollick, C, 1988) |
| "Hypertrophic cardiomyopathy is a heterogenous condition associated with a myriad of symptoms." | 2.61 | Lifestyle Modification and Medical Management of Hypertrophic Cardiomyopathy. ( Fischer, KL; Heitner, SB, 2019) |
| " This combination allows adequate dosing of disopyramide to achieve therapeutic goals." | 2.53 | Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice. ( Sherrid, MV, 2016) |
| "Disopyramide is a class Ia antiarrhythmic that historically was used for the treatment of arrhythmias; however, its contemporary use is often reserved for patients with HCM who are persistently symptomatic despite β-blockers or verapamil and have evidence of LVOT obstruction." | 2.52 | Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug. ( Coons, JC; Verlinden, NJ, 2015) |
| "Physicians treating hypertrophic cardiomyopathy (HCM) are faced with unique management challenges." | 2.43 | Pathophysiology of hypertrophic cardiomyopathy determines its medical treatment. ( Musat, D; Sherrid, MV, 2006) |
| "Disopyramide is a safe and effective treatment for LVOTO-related symptoms in childhood obstructive HCM." | 1.91 | Disopyramide is a safe and effective treatment for children with obstructive hypertrophic cardiomyopathy. ( Boleti, O; Cervi, E; Field, E; Kaski, JP; Norrish, G; Topriceanu, CC, 2023) |
| "Treatment with bisoprolol was well-tolerated and effective in relieving obstruction and improving symptoms in a significant proportion of patients with symptomatic obstructive HCM." | 1.72 | Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study. ( Caiazza, M; Calabrò, P; Cirillo, A; Dongiglio, F; Franco, F; Fusco, A; Limongelli, G; Lioncino, M; Mazzella, M; Monda, E; Moscarella, E; Pacileo, G; Palmiero, G; Rubino, M; Sepe, J; Verrillo, F, 2022) |
| "Disopyramide is a sodium channel blocker with negative inotropic properties that effectively reduces left ventricular outflow tract gradients in adults with hypertrophic cardiomyopathy, but its efficacy in children is uncertain." | 1.48 | Disopyramide use in infants and children with hypertrophic cardiomyopathy. ( Hanna, BD; Lin, KY; Miller, K; O'Connor, MJ; Ravishankar, C; Rossano, JW; Shaddy, RE, 2018) |
| "Initiation of disopyramide in the outpatient setting is safe and the risk of subsequent sudden cardiac death is low." | 1.46 | Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients. ( Adler, A; Chan, RH; Fourey, D; Gollob, MH; Hindieh, W; Rakowski, H; Weissler-Snir, A, 2017) |
| "Disopyramide was added in 221 (74%) patients and pharmacological control of symptoms was achieved in 141 (64%) patients." | 1.39 | Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil. ( Alviar, CL; Balaram, SK; Homel, P; Kim, B; Musat, D; Sherrid, MV; Shetty, A; Swistel, DG; Winson, G, 2013) |
| "Drug treatment of hypertrophic cardiomyopathy is the first-line treatment, at the onset of clinical signs and symptoms." | 1.35 | [Drug treatment for hypertrophic cardiomyopathy]. ( Gibelin, P, 2009) |
| "When severe COPD and obstructive hypertrophic cardiomyopathy (HCM) coexist, management is challenging and complex." | 1.35 | Oral disopyramide for the acute treatment of severe outflow obstruction in hypertrophic cardiomyopathy in the ICU setting. ( Sherrid, MV; Sirak, TE, 2008) |
| " Acute and long-term administration of propranolol lead to a significant reduction in heart rate at rest and during exercise." | 1.28 | Effect of propranolol and disopyramide on left ventricular function at rest and during exercise in hypertrophic cardiomyopathy. ( Hartmann, A; Hopf, R; Hör, G; Kaltenbach, M; Klepzig, H; Kober, G; Kühn, J; Maul, FD; Standke, R, 1992) |
| " However, the lower, sustained dosage of disopyramide was associated with a lower average serum level of 2." | 1.27 | Effects of disopyramide on left ventricular function: assessment by radionuclide cineangiography. ( Bates, R; Dibianco, R; Fletcher, RD; Gottdiener, JS; Sauerbrunn, BJ, 1983) |
| "Thus disopyramide, probably because of its negative inotropic action, is useful in the management of patients with HCM when LV outflow obstruction is the main cause of the clinical-hemodynamic findings." | 1.27 | [Beneficial effects of disopyramide on left ventricular outflow obstruction in a case of hypertrophic obstructive cardiomyopathy]. ( Contini, GM; Dore, L; Franceschino, V; Ibba, GV; Terrosu, P, 1984) |
| "Disopyramide serum levels were measured at the time of echocardiography." | 1.27 | Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. ( Delia, E; Dwyer, E; Sherrid, M, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (15.38) | 18.7374 |
| 1990's | 19 (36.54) | 18.2507 |
| 2000's | 7 (13.46) | 29.6817 |
| 2010's | 12 (23.08) | 24.3611 |
| 2020's | 6 (11.54) | 2.80 |
| Authors | Studies |
|---|---|
| Monda, E | 1 |
| Lioncino, M | 1 |
| Palmiero, G | 1 |
| Franco, F | 1 |
| Rubino, M | 1 |
| Cirillo, A | 1 |
| Verrillo, F | 1 |
| Fusco, A | 1 |
| Caiazza, M | 1 |
| Mazzella, M | 1 |
| Moscarella, E | 1 |
| Dongiglio, F | 1 |
| Sepe, J | 1 |
| Pacileo, G | 1 |
| Calabrò, P | 1 |
| Limongelli, G | 1 |
| Topriceanu, CC | 1 |
| Field, E | 1 |
| Boleti, O | 1 |
| Cervi, E | 1 |
| Kaski, JP | 1 |
| Norrish, G | 1 |
| Owens, AT | 1 |
| Masri, A | 1 |
| Abraham, TP | 1 |
| Choudhury, L | 1 |
| Rader, F | 1 |
| Symanski, JD | 1 |
| Turer, AT | 1 |
| Wong, TC | 1 |
| Tower-Rader, A | 1 |
| Coats, CJ | 1 |
| Fifer, MA | 2 |
| Olivotto, I | 1 |
| Solomon, SD | 1 |
| Watkins, HC | 1 |
| Heitner, SB | 2 |
| Jacoby, DL | 1 |
| Kupfer, S | 1 |
| Malik, FI | 1 |
| Meng, L | 1 |
| Sohn, R | 1 |
| Wohltman, A | 1 |
| Maron, MS | 2 |
| Hori, Y | 1 |
| Fujimoto, E | 1 |
| Nishikawa, Y | 1 |
| Nakamura, T | 1 |
| Rodriguez-Gonzalez, M | 1 |
| Pérez-Reviriego, ÁA | 1 |
| Castellano-Martinez, A | 1 |
| Cascales-Poyatos, HM | 1 |
| Rowin, EJ | 1 |
| Sridharan, A | 1 |
| Madias, C | 1 |
| Firely, C | 1 |
| Koethe, B | 1 |
| Link, MS | 1 |
| Maron, BJ | 2 |
| Adler, A | 1 |
| Fourey, D | 1 |
| Weissler-Snir, A | 1 |
| Hindieh, W | 1 |
| Chan, RH | 1 |
| Gollob, MH | 1 |
| Rakowski, H | 1 |
| O'Connor, MJ | 1 |
| Miller, K | 1 |
| Shaddy, RE | 1 |
| Lin, KY | 1 |
| Hanna, BD | 1 |
| Ravishankar, C | 1 |
| Rossano, JW | 1 |
| Fischer, KL | 1 |
| Sherrid, MV | 7 |
| Shetty, A | 1 |
| Winson, G | 1 |
| Kim, B | 1 |
| Musat, D | 2 |
| Alviar, CL | 1 |
| Homel, P | 1 |
| Balaram, SK | 1 |
| Swistel, DG | 1 |
| Sorajja, P | 1 |
| Ommen, SR | 2 |
| Nishimura, RA | 2 |
| Haruki, S | 2 |
| Minami, Y | 4 |
| Suzuki, A | 1 |
| Hagiwara, N | 4 |
| Verlinden, NJ | 1 |
| Coons, JC | 1 |
| Kajimoto, K | 4 |
| Kawana, M | 2 |
| Gibelin, P | 1 |
| Yashiro, B | 1 |
| Suzuki, T | 1 |
| Imai, T | 1 |
| Kasanuki, H | 4 |
| Philippakis, AA | 1 |
| Falk, RH | 1 |
| Teraguchi, M | 1 |
| Ikemoto, Y | 1 |
| Kobayashi, Y | 1 |
| Barac, I | 1 |
| McKenna, WJ | 1 |
| Elliott, PM | 1 |
| Dickie, S | 1 |
| Chojnowska, L | 1 |
| Casey, S | 1 |
| Elesber, A | 1 |
| Rihal, CS | 1 |
| Schaff, HV | 1 |
| Holmes, DR | 1 |
| Sirak, TE | 1 |
| Gottdiener, JS | 1 |
| Dibianco, R | 1 |
| Bates, R | 1 |
| Sauerbrunn, BJ | 1 |
| Fletcher, RD | 1 |
| Terrosu, P | 1 |
| Franceschino, V | 1 |
| Contini, GM | 1 |
| Dore, L | 1 |
| Ibba, GV | 1 |
| Murgo, JP | 1 |
| Pollick, C | 4 |
| Matsubara, H | 1 |
| Nakatani, S | 1 |
| Nagata, S | 1 |
| Ishikura, F | 1 |
| Katagiri, Y | 1 |
| Ohe, T | 1 |
| Miyatake, K | 1 |
| O'Gara, PT | 1 |
| McGovern, BA | 1 |
| Semigran, MJ | 1 |
| Kimball, BP | 1 |
| Bui, S | 1 |
| Wigle, ED | 2 |
| Gunsburg, DZ | 1 |
| Pearle, G | 1 |
| Pernat, A | 1 |
| Pohar, B | 1 |
| Horvat, M | 1 |
| Niki, K | 3 |
| Sugawara, M | 2 |
| Asano, R | 1 |
| Oka, T | 1 |
| Kondoh, Y | 1 |
| Tanino, S | 2 |
| Iwade, K | 2 |
| Magosaki, N | 1 |
| Hosoda, S | 2 |
| Tokudome, T | 1 |
| Mizushige, K | 1 |
| Ueda, T | 1 |
| Sakamoto, S | 1 |
| Matsuo, H | 1 |
| Sakai, Y | 1 |
| Hayashi, Y | 1 |
| Tomobuchi, Y | 1 |
| Hano, T | 1 |
| Nishio, I | 1 |
| Harada, T | 1 |
| Imamura, K | 1 |
| Matsuda, N | 1 |
| Shite, J | 1 |
| Yokota, Y | 1 |
| Nakatani, M | 1 |
| Takeuchi, Y | 1 |
| Tsumura, Y | 1 |
| Kawai, H | 1 |
| Ueno, H | 1 |
| Kawashima, T | 1 |
| Honda, Y | 1 |
| Hartmann, A | 1 |
| Kühn, J | 1 |
| Hopf, R | 1 |
| Klepzig, H | 1 |
| Standke, R | 1 |
| Kober, G | 1 |
| Maul, FD | 1 |
| Hör, G | 1 |
| Kaltenbach, M | 1 |
| Blanchard, DG | 1 |
| Ross, J | 1 |
| Tanabe, T | 1 |
| Takahashi, K | 1 |
| Yoshioka, K | 1 |
| Goto, Y | 1 |
| Millaire, A | 1 |
| Goullard, L | 1 |
| Decoulx, E | 1 |
| de Groote, P | 1 |
| Houdas, Y | 1 |
| Ducloux, G | 1 |
| Nagashima, J | 1 |
| Duncan, WJ | 1 |
| Tyrrell, MJ | 1 |
| Bharadwaj, BB | 1 |
| Sumimoto, T | 1 |
| Hamada, M | 1 |
| Ohtani, T | 1 |
| Shigematsu, Y | 1 |
| Fujiwara, Y | 1 |
| Sekiya, M | 1 |
| Hiwada, K | 1 |
| van der Wall, E | 1 |
| Sherrid, M | 1 |
| Delia, E | 1 |
| Dwyer, E | 1 |
| Kimball, B | 1 |
| Henderson, M | 1 |
| Miyajima, S | 1 |
| Aizawa, Y | 1 |
| Matsuoka, A | 1 |
| Okabe, M | 1 |
| Shibata, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control Trial[NCT02948998] | Phase 4 | 260 participants (Anticipated) | Interventional | 2018-05-14 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for disopyramide and Cardiomyopathy, Hypertrophic Obstructive
| Article | Year |
|---|---|
Lifestyle Modification and Medical Management of Hypertrophic Cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Calcium Channel Blockers; Cardiomyopathy, Hypertrophic; Cardiotonic Age | 2019 |
Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug.
Topics: Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Disopyramide; Humans | 2015 |
Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice.
Topics: Animals; Cardiomyopathy, Hypertrophic; Disopyramide; Electrocardiography; Humans; Hypertension; Vent | 2016 |
Pathophysiology of hypertrophic cardiomyopathy determines its medical treatment.
Topics: Adrenergic beta-Antagonists; Cardiomyopathy, Hypertrophic; Decision Trees; Defibrillators, Implantab | 2006 |
Effect of disopyramide on left ventricular pressure gradient in hypertrophic obstructive cardiomyopathy in comparison with propranolol--a case report.
Topics: Aged; Anti-Arrhythmia Agents; Blood Pressure; Cardiomyopathy, Hypertrophic; Disopyramide; Echocardio | 1999 |
Hypertrophic cardiomyopathy: prognosis with medical or surgical therapy.
Topics: Adrenergic beta-Antagonists; Adult; Calcium Channel Blockers; Cardiomyopathy, Hypertrophic; Child; D | 1991 |
6 trials available for disopyramide and Cardiomyopathy, Hypertrophic Obstructive
| Article | Year |
|---|---|
Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy.
Topics: Adult; Aged; Analysis of Variance; Blood Pressure; Cardiac Catheterization; Cardiomyopathy, Hypertro | 1995 |
Disopyramide improves the balance between myocardial oxygen supply and demand in patients with hypertrophic obstructive cardiomyopathy.
Topics: Adult; Aged; Blood Flow Velocity; Cardiac Catheterization; Cardiomyopathy, Hypertrophic; Coronary Ci | 1997 |
Effect of disopyramide on left ventricular pressure gradient in hypertrophic obstructive cardiomyopathy in comparison with propranolol--a case report.
Topics: Aged; Anti-Arrhythmia Agents; Blood Pressure; Cardiomyopathy, Hypertrophic; Disopyramide; Echocardio | 1999 |
Evaluation of disopyramide and mexiletine used alone and in combination for ventricular arrhythmias in patients with and without overt heart disease.
Topics: Administration, Oral; Adult; Aged; Cardiac Complexes, Premature; Cardiomyopathy, Dilated; Cardiomyop | 1991 |
Effect of disopyramide on systolic and early diastolic time intervals in patients with hypertrophic cardiomyopathy.
Topics: Adult; Aged; Blood Pressure; Cardiomyopathy, Hypertrophic; Diastole; Disopyramide; Female; Heart Rat | 1991 |
Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cardiomyopathy, Hypertrophic; Clinical Trials as | 1988 |
41 other studies available for disopyramide and Cardiomyopathy, Hypertrophic Obstructive
| Article | Year |
|---|---|
Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study.
Topics: Adult; Bisoprolol; Cardiomyopathy, Hypertrophic; Disopyramide; Humans; Retrospective Studies; Ventri | 2022 |
Disopyramide is a safe and effective treatment for children with obstructive hypertrophic cardiomyopathy.
Topics: Adolescent; Adult; Cardiomyopathy, Hypertrophic; Child; Child, Preschool; Disopyramide; Echocardiogr | 2023 |
Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3.
Topics: Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Disopyramide; Heart Failure; Humans; Sequoia | 2023 |
Left ventricular outflow tract pressure gradient changes after carvedilol-disopyramide cotherapy in a cat with hypertrophic obstructive cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Animals; Cardiomyopathy, Hypertrophic; Carvedilol; Cat Diseases; Cats; | 2020 |
[Disopyramide as coadjuvant treatment in obstructive hypertrophic cardiomyopathy].
Topics: Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Disopyramide; Humans | 2021 |
Prediction and Prevention of Sudden Death in Young Patients (<20 years) With Hypertrophic Cardiomyopathy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Calcium Channel Blockers; Ca | 2020 |
Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients.
Topics: Action Potentials; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Data | 2017 |
Disopyramide use in infants and children with hypertrophic cardiomyopathy.
Topics: Adolescent; Cardiomyopathy, Hypertrophic; Child; Child, Preschool; Disopyramide; Dose-Response Relat | 2018 |
Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cardiac Surgica | 2013 |
Symptomatic obstructive hypertrophic cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Aged; Cardiomyopathy, Hypertrophic; Diagnosis, Differential; Disease-Fr | 2013 |
Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Disopyramide; Dose-Respo | 2015 |
Synergistic effect of dual chamber pacing and disopyramide in obstructive hypertrophic cardiomyopathy.
Topics: Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Cardiomyopathy, Hypertrophic; Combined Modality | 2010 |
[Drug treatment for hypertrophic cardiomyopathy].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cardiomyop | 2009 |
Possible acute and chronic synergistic effect of dual chamber pacing and disopyramide in obstructive hypertrophic cardiomyopathy: a case report.
Topics: Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Cardiomyopathy, Hypertrophic; Combined Mod | 2010 |
Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Disopyramide; Echocardiography, D | 2010 |
Cardiac amyloidosis mimicking hypertrophic cardiomyopathy with obstruction: treatment with disopyramide.
Topics: Aged; Amyloidosis; Cardiomyopathies; Cardiomyopathy, Hypertrophic; Disopyramide; Humans; Magnetic Re | 2012 |
Effective disopyramide treatment in a boy with mid-ventricular hypertrophic obstructive cardiomyopathy.
Topics: Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Chest Pain; Child; Disopyramide; Heart Ventric | 2002 |
Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrop | 2005 |
Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Anti-Arrhythmia Agents; Calcium Channel Blocke | 2008 |
Oral disopyramide for the acute treatment of severe outflow obstruction in hypertrophic cardiomyopathy in the ICU setting.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Disopyramide; Dose-Respo | 2008 |
Effects of disopyramide on left ventricular function: assessment by radionuclide cineangiography.
Topics: Adult; Aged; Cardiomyopathy, Hypertrophic; Coronary Disease; Disopyramide; Heart; Heart Ventricles; | 1983 |
[Beneficial effects of disopyramide on left ventricular outflow obstruction in a case of hypertrophic obstructive cardiomyopathy].
Topics: Angina Pectoris; Cardiomyopathy, Hypertrophic; Disopyramide; Female; Humans; Middle Aged | 1984 |
Does outflow obstruction exist in hypertrophic cardiomyopathy?
Topics: Cardiomyopathy, Hypertrophic; Disopyramide; Heart Ventricles; Humans; Myocardial Contraction | 1982 |
Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide.
Topics: Administration, Oral; Adult; Aortic Stenosis, Subvalvular; Cardiomyopathy, Hypertrophic; Disopyramid | 1982 |
Effects of disopyramide on diastolic function in hypertrophic cardiomyopathy.
Topics: Cardiomyopathy, Hypertrophic; Diastole; Disopyramide; Humans; Ventricular Function, Left | 1995 |
Effects of disopyramide on left ventricular diastolic function in hypertrophic cardiomyopathy.
Topics: Cardiac Catheterization; Cardiomyopathy, Hypertrophic; Diastole; Disopyramide; Female; Hemodynamics; | 1994 |
Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy.
Topics: Adolescent; Adult; Aged; Cardiomyopathy, Hypertrophic; Disopyramide; Dose-Response Relationship, Dru | 1993 |
Mid-systolic drop in left ventricular ejection velocity in obstructive hypertrophic cardiomyopathy--the lobster claw abnormality.
Topics: Acceleration; Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Blood Flow Velocity; Calciu | 1997 |
Heart conduction disturbances and cardiovascular collapse after disopyramide and low-dose metoprolol in a patient with hypertrophic obstructive cardiomyopathy.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Dis | 1997 |
Dynamic outflow obstruction due to the transient extensive left ventricular wall motion abnormalities caused by acute myocarditis in a patient with hypertrophic cardiomyopathy: reduction in ventricular afterload by disopyramide.
Topics: Acute Disease; Aged; Cardiomyopathy, Hypertrophic; Coronary Angiography; Disopyramide; Echocardiogra | 1999 |
An equation to predict the changes in peak left ventricular pressure in hypertrophic obstructive cardiomyopathy after treatment: application to the administration of disopyramide.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiac Catheterization; Cardiomyopathy, Hypertrophic; Disopyra | 1999 |
[Efficacy of continuous intravenous drip infusion of disopyramide in hypertrophic obstructive cardiomyopathy during cardiogenic shock: a case report].
Topics: Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Disopyramide; Female; Humans; Infusions, Intra | 2000 |
[Clinical and echocardiographic evaluation of the effects of atrial defibrillation in patients with idiopathic cardiomyopathy].
Topics: Adult; Atrial Fibrillation; Blood Pressure; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; D | 1992 |
Effect of propranolol and disopyramide on left ventricular function at rest and during exercise in hypertrophic cardiomyopathy.
Topics: Administration, Oral; Adult; Cardiac Output; Cardiomyopathy, Hypertrophic; Disopyramide; Echocardiog | 1992 |
Efficiency of disopyramide in hypertrophic cardiomyopathy during stress states.
Topics: Adolescent; Adult; Cardiomyopathy, Hypertrophic; Disopyramide; Echocardiography, Doppler; Exercise; | 1992 |
[Doppler and echocardiographic assessments of effects of disopyramide on non-obstructive hypertrophic cardiomyopathy].
Topics: Adult; Aged; Blood Flow Velocity; Blood Pressure; Cardiomyopathy, Hypertrophic; Diastole; Disopyrami | 1991 |
Disopyramide as a negative inotrope in obstructive cardiomyopathy in children.
Topics: Cardiomyopathy, Hypertrophic; Carnitine; Child; Disopyramide; Ductus Arteriosus, Patent; Echocardiog | 1991 |
Disopyramide in hypertrophic cardiomyopathy.
Topics: Cardiomyopathy, Hypertrophic; Disopyramide; Exercise; Heart; Humans; Stroke Volume | 1990 |
Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy.
Topics: Aged; Aged, 80 and over; Cardiomyopathy, Hypertrophic; Disopyramide; Echocardiography; Echocardiogra | 1988 |
Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cardiac Output; Cardiomyopathy, Hypertrophic; Disopyramide; | 1988 |
Danger of use of disopyramide in patients with hypertrophic obstructive cardiomyopathy. An electrophysiologic study.
Topics: Cardiac Pacing, Artificial; Cardiomyopathy, Hypertrophic; Disopyramide; Drug Evaluation; Electrocard | 1988 |